Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 238 results for "Tecfidera Treated Patients"

One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis

Over Half of Audited Multiple Sclerosis Patients Currently Tre...

BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 day ago

3 images for "Tecfidera Treated Patients"

ABC News 4 Charleston, 1 day ago
Global News Canada, 2 months ago
Review Seeker, 4 months ago

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

News Categories Clinical Trials Research News Industry Trends Agency
 Pharmscope10 hours ago
American Enterprise Institute

Obamacare drug benefits block access to vital medicines

[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...
 World Socialist Web Site2 weeks ago Obamacare shortchanges patients with chronic disease  American Enterprise Institute1 month ago Under Obamacare's "Closed Formularies" Patients With Serious Diseases Don't Get Access to Vital And Very Costly Medicines  Forbes.com1 month ago

British Columbia to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis

/CNW/ - Biogen Idec Canada announces today that TECFIDERA (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERA is a first-line oral treatment for adults with relapsing-remitting ...
 CEOWorld Magazine4 weeks ago MS Awareness Month Brings Good News for Ontarians: Province to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis  TickerTech.com1 month ago
Jutia Group

Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Introduction The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies.
 Pettinga Financial Advisors3 weeks ago Market Update (NASDAQ:BIIB): Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year  Jutia Group14 hours ago Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company sponsored presentations highlighting key data from its industry leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurolog  TeleTrader.com1 month ago Data from Biogen Idec's Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses  Reuters1 month ago
Motley Fool

Biogen Stock's Tecfidera Embarrasses Wall Street

It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...
 Motley Fool8 hours ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera  FDA News6 days ago Biogen MS blockbuster Tecfidera earns high marks for safety  FiercePharma3 weeks ago MS Drug Tecfidera More Trouble Than It's Worth?  EMax Health1 month ago
Motley Fool

Why the Market Is Wrong About This Popular Marijuana Stock

Few areas of disease treatment have captured investors' attention as fully as medical marijuana has this year. While medical marijuana dispensaries have grabbed the spotlight lately, there are also biotechs attempting to create life-enhancing ...
 Motley Fool2 months ago

Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). The trial will assess the safety, tolerability ...
 Pharmaceutical Business Review5 days ago Alkermes takes its Tecfidera beater into clinical trials for MS  FierceBiotech6 days ago
Pharma Letter

NICE issues positive draft FAD guidance on Tecfidera11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) today for US biotech firm Biogen Idec's (Nasdaq: BIIB) new oral multiple sclerosis (MS) drug Tecfidera ...
 Pharma Letter1 week ago

MS pill Tecfidera available on NHS in England and Wales

The new MS pill Tecfidera (also known as dimethyl fumarate) has received the final stamp of approval from NICE, and should now be freely available on the NHS in England and Wales to people with active relapsing remitting MS. After an initial ...
 Noodls1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less